ASH 2014: CAR-T cell therapies generate buzz
This article was originally published in Scrip
Excitement around chimeric antigen receptor (CAR) T cell therapies has been building during the past year, because of the potential to essentially cure significant numbers of patients with hard to treat cancers, and the buzz came to a fever pitch during the American Society of Hematology (ASH) annual meeting in San Francisco from 6 to 9 December.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.